MeSH term
Frequency | Condition_Probility | Humans | 20 | 0.0 |
Adult | 5 | 0.0 |
Aged | 3 | 0.0 |
Aged, 80 and over | 2 | 0.0 |
*Antigens, Neoplasm | 4 | 2.0 |
Carbonic Anhydrases/*analysis | 2 | 40.0 |
Comparative Study | 3 | 0.0 |
Female | 8 | 0.0 |
Immunohistochemistry | 7 | 0.0 |
Middle Aged | 4 | 0.0 |
Neoplasm Proteins/*analysis | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 7 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 3 | 0.0 |
*Carbonic Anhydrases | 2 | 33.0 |
Cell Hypoxia | 3 | 1.0 |
Research Support, U.S. Gov't, P.H.S. | 5 | 0.0 |
Drug Resistance, Neoplasm | 2 | 0.0 |
Survival Analysis | 3 | 0.0 |
Male | 5 | 0.0 |
Necrosis | 2 | 0.0 |
Prognosis | 2 | 0.0 |
Oligonucleotide Array Sequence Analysis | 2 | 0.0 |
Blotting, Western | 3 | 0.0 |
Cell Line, Tumor | 3 | 0.0 |
Plasmids/metabolism | 2 | 0.0 |
RNA, Messenger/metabolism | 2 | 0.0 |
*Cell Hypoxia | 2 | 2.0 |
Tumor Cells, Cultured | 4 | 0.0 |
Promoter Regions (Genetics) | 2 | 0.0 |
Up-Regulation | 2 | 0.0 |
Carbonic Anhydrases/genetics/*metabolism | 2 | 66.0 |
Amino Acid Sequence | 2 | 0.0 |
Molecular Sequence Data | 2 | 0.0 |
Phenotype | 2 | 0.0 |
Child | 3 | 0.0 |
Neutralization Tests | 4 | 0.0 |
Cloning, Molecular | 2 | 0.0 |
Adolescent | 2 | 0.0 |
Age Factors | 2 | 0.0 |
Antibodies, Viral/*analysis | 2 | 3.0 |
Child, Preschool | 2 | 0.0 |
Infant | 2 | 0.0 |
Serotyping | 3 | 1.0 |